Volume 23 Issue 5
May  2025
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2025  >  23(5): 780-784
LIU Lin, XIE Zhibin, WANG Meng. Clinical observation of first-line treatment with Brentuximab Vedotin combined with chemotherapy in advanced classical Hodgkin lymphoma[J]. Chinese Journal of General Practice, 2025, 23(5): 780-784. doi: 10.16766/j.cnki.issn.1674-4152.004000
Citation: LIU Lin, XIE Zhibin, WANG Meng. Clinical observation of first-line treatment with Brentuximab Vedotin combined with chemotherapy in advanced classical Hodgkin lymphoma[J]. Chinese Journal of General Practice, 2025, 23(5): 780-784. doi: 10.16766/j.cnki.issn.1674-4152.004000
shu

Clinical observation of first-line treatment with Brentuximab Vedotin combined with chemotherapy in advanced classical Hodgkin lymphoma

doi: 10.16766/j.cnki.issn.1674-4152.004000

  • Department of Hematology, the First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui 233004, China

Funds:

 2023AH052011

 2022byzd048

 2022byzd053

  • Received Date: 2024-10-28
    Available Online: 2025-08-14
    Abstract
  •   Objective  To evaluate the effect of Brentuximab Vedotin (BV) combined with doxorubicin (A), vindesine (V), and dacarbazine (D) (BV-AVD-regimen) as first-line treatment for advanced classical Hodgkin lymphoma (cHL).  Methods  Clinical data of 10 patients with advanced cHL admitted to the Department of Haematology, the First Affiliated Hospital of Bengbu Medical University, from August 2021 to January 2023 with first-line application of the BV-AVD regimen were retrospectively analyzed. Data reviewed included general characteristics [gender, age, pathological type, primary site, stage, international prognostic score (IPS), and immunohistochemistry], treatment response, follow-up outcomes, and adverse reactions.  Results  Among the 10 patients, 6 were male and 4 were female, with a mean age of (44.7±13.3) years. Pathologically, 6 cases were classified as nodular sclerosis type and 4 as mixed cellularity type. Eight patients initially presented with superficial lymphadenopathy, while abdominal pain and retrosternal pain were reported in one case each. Seven patients were diagnosed with stage Ⅳ disease, and 5 had an international prognostic score (IPS) of ≥4. B symptoms were observed in 5 cases at diagnosis. Immunohistochemical analysis revealed EBER positivity in 5 patients and CD163 positivity in 3. After 2 cycles of treatment, the objective response rate (ORR) was 100%, with a complete response (CR) rate of 80%. Among the 9 evaluable patients after 6 cycles, both the ORR and CR rates were 89%. The median overall survival (OS) and progression-free survival (PFS) were not reached during follow-up. Patients with CD163 positivity had significantly shorter OS and PFS compared to CD163-negative patients (P=0.007 and P=0.001, respectively). The most common adverse events included fatigue (8 cases), nausea (8 cases), neutropenia (7 cases), febrile neutropenia (6 cases), and peripheral neuropathy (6 cases). Grade 3 adverse events occurred in only 2 patients.  Conclusion  The short-term follow-up indicates that fist-line BV-AVD treatment is effective in patients with advanced cHL, with manageable adverse effects.

     

    • FullText(HTML)
  • loading
    • References(22)
  • [1]
    BRICE P, DE KERVILER E, FRIEDBERG J W. Classical Hodgkin lymphoma[J]. Lancet, 2021, 398(10310): 1518-1527.
    [2]
    MUNIR F, HARDIT V, SHEIKH I N, et al. Classical Hodgkin lymphoma: from past to future-a comprehensive review of pathophysiology and therapeutic advances[J]. Int J Mol Sci, 2023, 24(12): 10095. DOI: 10.3390/ijms241210095.
    [3]
    KHAN M, HAGEMEISTER F, WANG M, et al. A review of pathobiology and therapies for classic Hodgkin lymphoma[J]. Blood Rev, 2022, 55: 100949. DOI: 10.1016/j.blre.2022.100949.
    [4]
    李洁, 张勇, 张越, 等. 维布妥昔单抗治疗淋巴瘤的研究进展[J]. 中国癌症防治杂志, 2022, 14(6): 693-697.

    LI J, ZHANG Y, ZHANG Y, et al. Research progress of vibutuximab in the treatment of lymphoma[J]. Chinese Journal of Oncology Prevention and Treatment, 2022, 14(6): 693-697
    [5]
    蔡铭慈, 许彭鹏, 赵维莅. 维布妥昔单抗治疗CD30阳性淋巴瘤的研究进展[J]. 中华血液学杂志, 2023, 44(1): 81-86.

    CAI M C, XU P P, ZHAO W L. Advances in the treatment of CD30 positive lymphoma with brentuximab vedotin[J]. Chinese Journal of Hematology, 2023, 44(1): 81-86.
    [6]
    中国抗癌协会血液肿瘤专业委员会, 中华医学会血液学分会, 中国霍奇金淋巴瘤工作组. 中国霍奇金淋巴瘤的诊断与治疗指南(2022年版)[J]. 中华血液学杂志, 2022, 43(9): 705-715.

    Hematological Oncology Committee of China Anti-cancer Association; Chinese Society of Hematology, Chinese Medical Association; Chinese Working Group for Hodgkin Lymphoma. The guidelines for diagnosis and treatment of Hodgkin lymphoma in China (2022)[J]. Chinese Journal of Hematology, 2022, 43(9): 705-715.
    [7]
    RICARD F, CHESON B, BARRINGTON S, et al. Application of the Lugano classification for initial evaluation, staging, and response assessment of Hodgkin and Non-Hodgkin lymphoma: the PRoLoG consensus initiative (part 1-clinical)[J]. J Nucl Med, 2023, 64(1): 102-108.
    [8]
    FREITES-MARTINEZ A, SANTANA N, ARIAS-SANTIAGO S, et al. Using the common terminology criteria for adverse events (CTCAE-version 5.0) to evaluate the severity of adverse events of anticancer therapies. CTCAE versión 5.0. evaluación de la gravedad de los eventos adversos dermatológicos de las terapias antineoplásicas[J]. Actas Dermosifiliogr (Engl Ed), 2021, 112(1): 90-92.
    [9]
    GHALAMKARI M, KHATUNI M, TOOGEH G, et al. Reversible acute lung injury due to bleomycin[J]. Tanaffos, 2022, 21(2): 253-256.
    [10]
    马梦雪, 乔淑凯. HIV阳性原发骨骼肌外周T细胞淋巴瘤非特指型并发横纹肌溶解1例及文献复习[J]. 中华全科医学, 2024, 22(8): 1443-1445. doi: 10.16766/j.cnki.issn.1674-4152.003655

    MA M X, QIAO S K. HIV positive primary skeletal muscle peripheral T cell lymphoma, not otherwise specified with complex rhabdomyolysis: a case report and literature review[J]. Chinese Journal of General Practice, 2024, 22(8): 1443-1445. doi: 10.16766/j.cnki.issn.1674-4152.003655
    [11]
    LI Z, GUO W, BAI O. Mechanism of action and therapeutic targeting of CD30 molecule in lymphomas[J]. Front Oncol, 2023, 13: 1301437. DOI: 10.3389/fonc.2023.1301437.
    [12]
    PRINCE H M, HUTCHINGS M, DOMINGO-DOMENECH E, et al. Anti-CD30 antibody-drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives[J]. Ann Hematol, 2023, 102(1): 13-29.
    [13]
    STRAUS D J, DŁUGOSZ-DANECKA M, CONNORS J M, et al. Brentuximab vedotin with chemotherapy for stage Ⅲ or Ⅳ classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial[J]. Lancet Haematol, 2021, 8(6): e410-e421.
    [14]
    中国临床肿瘤学会(CSCO)淋巴瘤专家委员会. 维布妥昔单抗治疗CD30阳性淋巴瘤临床应用指导原则中国专家共识(2022年版)[J]. 白血病·淋巴瘤, 2022, 31(8): 449-458.

    Lymphoma Expert Committee of Chinese Society of Clinical Oncology (CSCO). Chinese expert consensus on principles for clinical practice of brentuximab vedotin in CD30-positive lymphoma (2022 version)[J]. Journal of Leukemia and Lymphoma, 2022, 31(8): 449-458.
    [15]
    GUA T, LO M, YOUNG R, et al. Evaluation of pulmonary toxicities in lymphoma patients receiving brentuximab vedotin[J]. Leuk Lymphoma, 2022, 63(12): 3008-3011.
    [16]
    STEINER R E, HWANG S R, KHURANA A, et al. Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma[J]. Blood Adv, 2023, 7(24): 7485-7493.
    [17]
    SUREDA A, DOMINGO-DOMENECH E, GAUTAM A. Neutropenia during frontline treatment of advanced Hodgkin lymphoma: incidence, risk factors, and management[J]. Crit Rev Oncol Hematol, 2019, 138: 1-5.
    [18]
    STRAUS D, COLLINS G, WALEWSKI J, et al. Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage Ⅲ/Ⅳ Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy[J]. Leuk Lymphoma, 2020, 61(12): 2931-2938.
    [19]
    TAMMA R, INGRAVALLO G, GAUDIO F, et al. The tumor microenvironment in classic Hodgkin ' s lymphoma in responder and no-responder patients to first line ABVD therapy[J]. Cancers (Basel), 2023, 15(10): 2803. DOI: 10.3390/cancers15102803.
    [20]
    MENNDEZ V, SOLRZANO J L, FERNANDEZ S, et al. The Hodgkin lymphoma immune microenvironment: turning bad news into good[J]. Cancers (Basel), 2022, 14(5): 1360. DOI: 10.3390/cancers14051360.
    [21]
    AHMED H A S, RASLAN W F, DEIFALLA A H S, et al. CD163 is a predictive biomarker for prognosis of classical Hodgkin ' s lymphoma in Saudi patients[J]. Mol Clin Oncol, 2019, 11(1): 67-76.
    [22]
    SKYTTHE M K, GRAVERSEN J H, MOESTRUP S K. Targeting of CD163+ macrophages in inflammatory and malignant diseases[J]. Int J Mol Sci, 2020, 21(15): 5497. DOI: 10.3390/ijms21155497.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (8) PDF downloads(1) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return